Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

AVEO Pharmaceuticals Inc. (AVEO) (AVEO)

3.75   0.08 (2.18%) 04-09 16:00
Open: 3.79 Pre. Close: 3.67
High: 3.89 Low: 3.68
Volume: 142,123 Market Cap: 60M
AVEO Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing and commercializing novel cancer therapeutics.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.786 - 3.801 3.801 - 3.817
Low: 3.514 - 3.529 3.529 - 3.545
Close: 3.645 - 3.671 3.671 - 3.699

Technical analysis

as of: 2020-04-09 3:25:29 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 5.31     One year: 6.21
Support: Support1: 3.12    Support2: 2.23
Resistance: Resistance1: 4.55    Resistance2: 5.31
Pivot: 3.49
Moving Average: MA(5): 3.62     MA(20): 3.34
MA(100): 5.43     MA(250): 6.84
MACD: MACD(12,26): -0.13     Signal(9): -0.24
Stochastic oscillator: %K(14,3): 63.13     %D(3): 60.99
RSI: RSI(14): 50.06
52-week: High: 11.20  Low: 2.23  Change(%): -63.2
Average Vol(K): 3-Month: 21892  10-Days: 20870

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
AVEO has closed below upper band by 37.1%. Bollinger Bands are 5.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.

Aveo bails on ficlatuzumab study amid Covid-19
Citing clinical trial sites' urgent shift towards fighting the COVID-19 pandemic, AVEO Oncology (NASDAQ:AVEO) and collaboration partner Biodesix have decid

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 16.08
Shares Float (M) 13.48
% Held by Insiders 0.25
% Held by Institutions 27.15
Shares Short (K) 1630
Shares Short P. Month (K) 1620

Stock Financials

EPS 0.610
Book Value (p.s.) 0.920
PEG Ratio
Profit Margin 32.60
Operating Margin -1.30
Return on Assets (ttm) -0.6
Return on Equity (ttm)
Qtrly Rev. Growth -48.5
Gross Profit (p.s.) 0.674
Sales Per Share 1.791
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -2.92
Levered Free Cash Flow (M) -1.67

Stock Valuations

P/E 6.15
P/E Growth Ratio 0.02
P/BV 4.08
P/CF -20.65

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2020-02-19
Last Split Ratio 0.1
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.